Letrozol Viatris (Letrozole)

Letrozole reversibly binds to the aromatase enzyme, a non‑steroidal inhibitor that blocks the conversion of androstenedione and testosterone into estrone and estradiol. By reducing circulating estrogen, it deprives estrogen‑dependent breast cancer cells of a growth stimulus, slowing disease progression.

The dosage regimen is determined by the prescribing physician based on the patient’s clinical condition, disease stage, and tolerance. Letrozole is typically administered once daily as an oral tablet, but the exact strength and quantity must follow the prescriber’s order and local regulatory guidelines.

Letrozole is contraindicated in pregnancy because it can disrupt estrogen synthesis essential for fetal development. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after the last dose. Breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Letrozole is a third‑generation, non‑steroidal aromatase inhibitor with high potency and a long half‑life, allowing once‑daily dosing. Compared with earlier agents such as anastrozole or exemestane, letrozole often provides greater estrogen suppression, which may translate into improved disease control in certain patient populations, though individual response varies.

The product should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the tablets away from excessive heat, humidity, and direct sunlight. Do not use if the packaging is damaged or the tablets appear discoloured.

Letrozol Viatris is taken orally, usually as a whole tablet swallowed with water. It is generally recommended to take the dose at the same time each day, with or without food, as directed by the healthcare professional. Patients should follow the prescriber’s instructions regarding timing and any concomitant medications.

Serious adverse events, although uncommon, include deep vein thrombosis, pulmonary embolism, severe liver injury, bone fractures due to decreased estrogen, and cardiovascular events such as myocardial infarction. Patients should be monitored for signs of these conditions and advised to seek immediate medical attention if symptoms arise.

Letrozol Viatris is contraindicated in premenopausal women, pregnant or breastfeeding individuals, and patients with known hypersensitivity to letrozole or any excipients in the formulation. Caution is also advised for patients with severe hepatic impairment or a history of thromboembolic disorders; the drug should be avoided unless a specialist determines that benefits outweigh the risks.